Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
T Bieber - Nature reviews Drug discovery, 2022 - nature.com
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …
[HTML][HTML] Prevalence and incidence of atopic dermatitis: a systematic review
S Bylund, LB von Kobyletzki, M Svalstedt… - Acta dermato …, 2020 - ncbi.nlm.nih.gov
The primary objective of this study was to systematically review and analyse epidemiological
studies of the prevalence and incidence of atopic dermatitis (AD) during childhood and …
studies of the prevalence and incidence of atopic dermatitis (AD) during childhood and …
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA …
A Wollenberg, A Blauvelt… - British Journal of …, 2021 - academic.oup.com
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017
MR Laughter, MBC Maymone… - British Journal of …, 2021 - academic.oup.com
Summary Background The Global Burden of Disease (GBD) Study provides an annually
updated resource to study disease‐related morbidity and mortality worldwide. Objectives …
updated resource to study disease‐related morbidity and mortality worldwide. Objectives …
[HTML][HTML] Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study
JI Silverberg, S Barbarot, A Gadkari, EL Simpson… - Annals of Allergy …, 2021 - Elsevier
Background Little is known on the current global prevalence of atopic dermatitis (AD) in the
pediatric population. Objective To estimate the real-world global prevalence of AD in the …
pediatric population. Objective To estimate the real-world global prevalence of AD in the …
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase …
EL Simpson, JP Lacour, L Spelman… - British Journal of …, 2020 - academic.oup.com
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy
BJH Dierick, T van der Molen… - Expert review of …, 2020 - Taylor & Francis
Introduction Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately
20% of the global population. Few studies describe the burden of the totality of these …
20% of the global population. Few studies describe the burden of the totality of these …
Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis
AS Halling, N Loft, JI Silverberg… - Journal of the American …, 2021 - Elsevier
Background Dupilumab, the first biological drug to be approved for the treatment of
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …
Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial
K Reich, K Kabashima, K Peris, JI Silverberg… - JAMA …, 2020 - jamanetwork.com
Importance Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy …
disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy …
[HTML][HTML] Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population
ZCC Fuxench, JK Block, M Boguniewicz, J Boyle… - Journal of Investigative …, 2019 - Elsevier
Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The
objectives of this study were to determine the prevalence of atopic dermatitis in the …
objectives of this study were to determine the prevalence of atopic dermatitis in the …